Salute e Benessere

WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating

As a state-of-the-art pharmaceutical manufacturing facility, the Couvet site plays a vital role in WuXi AppTec's CRDMO business model by providing both clinical and commercial scale manufacturing capabilities for oral solid dosage forms. The facility was designed with industry-leading energy efficiency and environmental standards and was built to accommodate future sustainable growth. As a state-of-the-art pharmaceutical manufacturing facility, the Couvet site plays a vital role in WuXi...
PR Newswire
14/11/2024

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

The article continued: As reported by The Guardian, a new study is raising hopes of treating aggressive cancers by zapping rogue DNA that helps tumors thrive and become resistant to chemotherapy. Showing the shifting market, researchers at Statista recently released a report showing the Top 5 Oncology Products Worldwide by Market Share in 2017 and 2024. The article continued:As reportedbyThe Guardian,a new study is raising hopes of treating aggressive cancers by zapping rogue DNA that...
PR Newswire
14/11/2024

Tilray Medical Launches its First Commercial “Grown in Germany” Medical Cannabis…

On July 15, 2024, Tilray Medical was the first to receive a new cannabis cultivation license issued under MedCanG. This license allows Aphria RX to cultivate and manufacture a broad range of commercially available medical cannabis in Germany. The strains to be grown at this indoor facility have been carefully selected from top performing varieties popular with patients across Canada.Tilray's Chief Strategy Officer and Head of International, Denise Faltischek, said, "We are excited to...
Nasdaq GlobeNewswire
14/11/2024

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056…

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's DiseaseActive immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations100% of patients receiving ACI-7104.056 responded against the target antigenACI-7104.056 is well tolerated with no clinically relevant safety issues reported to dateLausanne, Switzerland, November 14, 2024– AC...
Nasdaq GlobeNewswire
14/11/2024

Bridge to Life Ltd. Achieves Global Milestone Using Hypothermic Oxygenated…

"We are proud to be the liver transplantation center that has reached this milestone for Bridge to Life," commented Russell Bolton, Head of Liver Services, UHB Liver Services Unit. "As one of the largest transplantation centers in the UK, providing a comprehensive range of hepatology (liver medicine), liver surgery, and liver transplantation services to our patients, UHB has been at the forefront of adopting new technologies that can make more livers available to patients in…
PR Newswire
14/11/2024

Neuraxpharm reports another year of sustained growth and international expansion

International expansion across Europe and beyond International expansion acrossEuropeand beyond Since its creation over 35-years ago, and its subsequent acquisition by Permira in 2020, Neuraxpharm has pursued its objective of becoming the partner of choice in CNS. Building on this heritage, and following its rebranding in 2018, Neuraxpharm has established itself as a leading European specialty pharma company focused on the treatment of psychiatric and neurological CNS disorders...
PR Newswire
14/11/2024

Suvoda Awarded US Patent for its eCOA Software Architecture

The patent demonstrates the power of Suvoda eCOA: expedited questionnaire creation, translation, localization, and deployment so clinical trial sponsors can launch their studies more efficiently. While eCOA is traditionally a bottleneck in clinical trial implementation, Suvoda eCOA and its SQDL tool enable sponsors to deliver high quality questionnaires in a matter of hours, instead of days. The patent demonstratesthe power of Suvoda eCOA: expedited questionnaire creation, translation,...
PR Newswire
14/11/2024

Sanofi Partners With Beano & Breakthrough T1D UK to Raise Awareness of…

T1D is an autoimmune, complex, and lifelong condition – and it can happen to anyone at any age even without family history.[1] It can be a challenging disease with lifelong clinical, economic, and emotional unmet needs for patients and families. In the UK, there is a growing prevalence where approximately 400,000 people are living with the disease, including about 36,000 people 19 years of age and younger.[2],[3] It is known that T1D is not caused by diet or lifestyle, however, currently the…
PR Newswire
14/11/2024

Register Now for HOTEL & SHOP PLUS 2025 at Shanghai

Products and Benefits from HSP 2025 Products and Benefits from HSP 2025 The exhibition will showcase a variety of high-end, eco-friendly materials and products across categories like construction, design, smart hotels, lighting, retail, smart office, landscaping, cleaning and operation and maintenance, etc. It will also feature creative designs and advanced intelligent systems. Hall E features construction materials like architectural decoration, ceramics, and outdoor furniture,...
PR Newswire
14/11/2024

Xeltis announces FDA Breakthrough Device Designation for aXessTM and first…

Eliane Schutte, Chief Executive Officer, Xeltis commented:"We are in a transformative period for Xeltis, and this designation from the FDA is great recognition of the potential importance of our highly novel technology. We are also extremely proud that the first patient in our US pivotal trial has now been treated, and this clinical achievement provides us with significant momentum as we advance towards commercialization." Eliane Schutte, Chief Executive Officer, Xeltis commented…
PR Newswire
14/11/2024

Mallinckrodt announces the 2024 Winner of the Extracorporeal Immunomodulation…

The EIA-winning project was submitted by Dr Andrea Varkonyi, of the South-Pest Central Hospital, National Institute of Hematology and Infectiology's Department of Hematology and Stem Cell Transplantation, in Budapest, Hungary. Her team will carry out a retrospective and prospective study, comparing ruxolitinib alone to ruxolitinib combined with ECP therapy in the treatment of acute and chronic GvHD. They will also evaluate the impact of ECP on the development of transplant-associated thrombotic…
PR Newswire
14/11/2024

Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for…

Dr. Peter Forsell, CEO of Implantica, says, "The incredible enthusiasm for RefluxStop™ among top surgeons at the recent annual American Foregut Society and European Foregut Society meetings is a testimony to the immense demand for innovation in the surgical treatment of GERD. This support is growing fast, fueled by RefluxStop's excellent clinical outcomes, both in our pivotal 5-year study but also supported by multiple centers around Europe presenting their equally excellent results. This…
PR Newswire
14/11/2024

City of Savonlinna has chosen Aino's SaaS platform

Yet another Finnish public organization, the City of Savonlinna, has chosen Aino's SaaS platform. As part of a strong initiative to build a more sustainable work environment, to manage staffing needs and secure the competence supply, to be a more attractive employer. The agreement includes a total of 1100 employees and the Aino SaaS platform is in production use from the fourth quarter of 2024. “As a public employer we should always aim for a holistic and systematic approach to our...
Nasdaq GlobeNewswire
14/11/2024

Casino Group: 2028 Strategic Plan

Casino Group: a strategic plan to achievethe best of brands in convenience retailing Paris, 14 November 2024 A strategic plan named "Renouveau 2028",aimed at becoming the best of brands in convenience retailing.Growth drivers based onthree key market segments : Being the go-to choice for day-to-day food shopping;Becoming a major player in Quick Meal Solutions;Being the leader in providing new everyday services.To kickstart this transformation, we will be...
Nasdaq GlobeNewswire
14/11/2024

Casino Group: Release of the Strategic Plan Presentation

RELEASE OF THE PRESENTATIONOF THE STRATEGIC PLAN The Group has released its Strategic Plan Presentation on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2024/11/2024-11-14-Casino-Strategic-Plan-Presentation.pdfAnalyst and investor contactsCharlotte Izabel +33 (0)6 89 19 88 33 [email protected] Relations +33 (0)1 53 65 24 [email protected] Press contacts...
Nasdaq GlobeNewswire
14/11/2024

Bioretec Ltd's business review January-September 2024: Launch of the RemeOs™…

July - September 2024 in brief July -September 2024in brief January- September 2024in brief This business review is unaudited. This is Bioretec's first business review for the third quarter, and comparison period figures have not been published earlier. Key figures Key events during July -September 2024 Alan Donze, CEO of Bioretec Ltd: " As I reflect on my first 100 days as CEO, I am both proud of the strides we have made and energized by the...
PR Newswire
14/11/2024

"Innovation Drive Development, Join Hands to Shape the Future" Singclean…

Among the highlights, Dr. Pavel Žigo, a leading orthopedic expert with over 40 years of experience, delivered a keynote on knee osteoarthritis treatments. Dr. Žigo shared insights on the effectiveness of Quickclean® injections, which have gained popularity acrossEuropefor its preventive benefits, even in patients without severe pain. He also discussed the latest cross-linked sodium hyaluronate product, SingOne, which promises to enhance long-term osteoarthritis care with personalized...
PR Newswire
14/11/2024

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

Dr. Chris Chen, CEO of WuXi Biologics, commented, "The increased capacity in Germany will allow us to continue to meet growing client demand for DP services, especially for prefilled syringes. Such investments further demonstrate our commitment to the Global Dual Sourcing strategy that ensures materials can be sourced and products manufactured at multiple sites within the company's global network. As a trusted partner to global healthcare companies and a significant contributor to the local…
PR Newswire
14/11/2024

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space…

Key Takeaways from the Multiple Sclerosis Pipeline Report Key Takeaways from the Multiple Sclerosis Pipeline Report Request a sample and discover the recent advances in multiple sclerosis treatment drugs @ Multiple Sclerosis Pipeline Report The multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and...
PR Newswire
13/11/2024

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Nov.13, 2024(GLOBE NEWSWIRE) --Paris, France, November 13, 2024Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares OutstandingTotal number of...
Nasdaq GlobeNewswire
13/11/2024

Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an…

The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue Integra LifeSciences Holdings Corporation(Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five...
Nasdaq GlobeNewswire
13/11/2024

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver…

PBC program (licensed to Ipsen):Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor) 1on track with expectations; encouraging feedback from healthcare providers and payers in the U.S.UK NICE reimbursement approved and first reimbursed sales in Germany in October 2024Next €26.5M milestone payment by Ipsen pending a third pricing and reimbursement approval in EuropeScientific progress in ACLF to be featured at The Liver...
Nasdaq GlobeNewswire
13/11/2024

Alvotech Reports Financial Results for the First Nine Months of 2024

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million, with Q3 product revenues contributing $62 millionLicense and other revenues for the first nine months of 2024 increased by $203 from the same period last year, to $211 million, with Q3...
Nasdaq GlobeNewswire
13/11/2024

PHAXIAM Reports Third-Quarter 2024 Financial Information

Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024."The third quarter of...
Nasdaq GlobeNewswire
13/11/2024
Altri  Comunicati